“clarus-ventures” Archives

in
Entry Author Date Location
Annexon Biosciences Lands $44,000,000 Series B Funding Round 06/23/16 San Francisco
GrayBug Vision Receives $44,500,000 Series B Funding 05/02/16 San Francisco
East Coast Biotech Roundup: PfizerGan, Nimbus, Intercept, Tesaro & More 04/08/16 Boston
Lumos Pharma Raises $34M to Fund Clinical Trials for CTD Drug 04/06/16 Texas
Lumos Pharma Receives $34,000,000 Series B Round 04/06/16 Texas
Entasis Therapeutics Garners $50,000,000 Series B Funding 04/05/16 Boston
AstraZeneca Spinout Entasis Snags $50M For Anti-Infective Treatments 04/04/16 Boston
Cancer Vaccines Back in Vogue as VCs Put $102M Into Gritstone Oncology 10/20/15 San Francisco
Nuvelution Pharma Secures New Funding 07/14/15 San Francisco
East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More 06/12/15 Boston
Lycera’s End Game? $104M Celgene Deal Could Lead to Buyout 06/11/15 Detroit Ann Arbor
Good Times Roll on for Biotech VCs As Clarus Bags New $500M Fund 06/09/15 Boston
AbbVie Snaps up Pharmacyclics, Pays Whopping $21B For Cancer Drug 03/05/15 National
Déjà Vu? Elan Alumni Start Antibody Firm to Fight Neurodegeneration 12/15/14 San Francisco
East Coast Biotech Roundup: Mergers, Rhythm, Regeneron, & More 05/09/14 Boston
Medtronic Scoops Up NJ-based Tyrx for $160M 01/06/14 New York
East Coast Biotech Roundup: Sarepta, Zalicus, Alkermes, & More 11/15/13 Boston
Catabasis Scores $32M Series B Round With IPO in Sight 11/15/13 Boston
Catabasis Pharmaceuticals Receives $32,400,000 Series B Financing 11/14/13 Boston
Aerie Gets Lukewarm Reception, Cuts IPO Price to $10 Per Share 10/25/13 New York
Ophthotech Prices IPO at $22 Per Share, Reels in $167M 09/24/13 New York
Aerie Pharma Eyes $58M IPO For Glaucoma Drug Push 09/18/13 New York
Biotech VCs, Stung by Startup Returns, Elbow into Royalty Financing 08/16/13 Boston
Ophthotech Eyes $85M IPO With Late-Stage Clinical Trial in Sight 08/15/13 New York
FDA Clears New Version of Tyrx’s Infection-Fighting Pacemaker Sleeve 07/09/13 New York
East Coast Life Sciences Roundup: Epizyme, Alkermes, Ophthotech, & More 05/31/13 Boston
Ophthotech Nabs $175M To Fund Late-Stage Trial For Eye Drug 05/29/13 New York
NanoString Technologies Maneuvers In Line for $86M IPO 05/20/13 Seattle
NanoString Technologies Garners $15,300,000 Series E Financing Round 12/03/12 Seattle
Pearl Therapeutics Secures $65,000,000 Series D Round 11/13/12 San Francisco
Page 1 of 4 next page »